AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Interleukin-5 receptor subunit alpha

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q01344

UPID:

IL5RA_HUMAN

Alternative names:

CDw125

Alternative UPACC:

Q01344; B3IU77; B4E2G0; Q14633; Q15469; Q6ISX9

Background:

Interleukin-5 receptor subunit alpha, also known as CDw125, plays a pivotal role in eosinophil survival, differentiation, and chemotaxis. This protein operates by forming a heterodimeric receptor with the CSF2RB subunit, which binds to interleukin-5, activating the JAK-STAT pathway through JAK2 stimulation. Its interaction with JAK2 in unstimulated conditions highlights its regulatory complexity.

Therapeutic significance:

Understanding the role of Interleukin-5 receptor subunit alpha could open doors to potential therapeutic strategies. Its involvement in eosinophil function suggests its potential as a target in diseases where eosinophils play a critical role.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.